{"entity":{"id":"nct05074810","kind":"trial","name":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","aka":[],"tldr":"A phase 1/2 trial of Sotorasib in non-small-cell lung cancer and small-cell lung cancer, run by Verastem, Inc., active and no longer recruiting.","summary":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients is a phase 1/2 interventional study registered as NCT05074810 by Verastem, Inc., with 153 participants planned, started 2022-04-12 and due to reach its primary completion in 2026-06. Interventions recorded: avutometinib and sotorasib, avutometinib and sotorasib and defactinib. Conditions listed: Non Small Cell Lung Cancer, KRAS Activating Mutation. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05074810","url":"https://clinicaltrials.gov/study/NCT05074810"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["sotorasib"],"companies":["verastem"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05074810","phase":"1/2","setting":"A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Verastem, Inc.","enrolled":153,"outcomes":[]},"route":"/trials/nct05074810/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/"}],"company":[{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/"}]}}